Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19.
Bristol-Myers Squibb (BMS) said that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) met the primary endpoint of a phase 3 trial in previously untreated malignant pleural mesothelioma (MPM).
Alexion Pharmaceuticals announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS).
Novartis has entered into an agreement with the US Food and Drug Administration (FDA) to conduct a clinical trial with the hydroxychloroquine in hospitalised COVID-19 patients.
Ascendis Pharma said that its prodrug candidate TransCon PTH has met key objectives in the phase 2 PaTH Forward trial in adult subjects with hypoparathyroidism.
The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.
Sinovac Biotech has secured approval in China to move ahead with a human clinical trial on an inactivated vaccine candidate against the SARS-CoV-2 virus (novel coronavirus or COVID-19).
Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.
Hope Biosciences has been given clearance from the US Food and Drug Administration (FDA) to move ahead with a phase 2 trial to evaluate its investigational stem cell therapy in providing immune support against COVID-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.